What is the 13F Pro Quality Score for IMRX?

13F Pro ranks Immuneering Corp (IMRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IMRX's current score at https://13fpro.ai/company/IMRX (free sign-up required for the full ranking).

Which hedge funds own the most IMRX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of IMRX include FMR, BlackRock,, Sanofi. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/IMRX as soon as new 13F filings post.

Where does 13F Pro source IMRX data?

All Immuneering Corp fundamentals and ownership data come directly from SEC EDGAR. Immuneering Corp files with the SEC under CIK 1790340. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IMRX in?

Immuneering Corp (IMRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IMRX research updated on 13F Pro?

IMRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Immuneering Corp(IMRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1790340 IMRX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $2.3M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

IMRX Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Immuneering Corp (IMRX), a Healthcare sector company. IMRX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $2.3m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Immuneering Corp reports net income of $-17.3M, free cash flow of $-16.5M. Top institutional holders of IMRX by reported 13-F value include FMR, BlackRock, Sanofi, based on the most recent SEC filings. IMRX trades on the Nasdaq exchange and files with the SEC under CIK 1790340. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Immuneering Corp directly from SEC EDGAR.

✦

Fun facts about Immuneering Corp

Quirks, history, and lore behind IMRX — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Maryland.
2
The Numbers
Minimal revenue — like most clinical-stage biotechs, it runs on cash burn rather than sales, with a market cap in the tens of millions of dollars.
3
The History
Founded in the 2010s and went public via a Nasdaq IPO, betting that a novel approach to disrupting cancer cell signaling could outmaneuver traditional oncology drugs.
4
The Secret
Its platform targets the RAS/MAPK pathway — one of the most mutated and historically undruggable routes in human cancer biology.
5
The Lore
The company's name is a mashup of "immune" and "engineering," signaling its ambition to harness the body's own biology against tumors.
6
The Giveaway
Ticker IMRX, pipeline led by IMM-1-104, and a name that sounds like something your immune system built in a lab — because that's exactly the point.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q2 2026

$-17.3M

Free Cash Flow

Q2 2026

$-16.5M

ROIC

Q2 2026

-39.9%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

—FY 2025

FY22 $317.0KFY23 $0.00FY24 —FY25 —

Net Income

+8.2% YoY

$-56.0MFY 2025

FY22 $-50.5MFY23 $-53.5MFY24 $-61.0MFY25 $-56.0M

Operating Income

+7.3% YoY

$-59.4MFY 2025

FY22 $-51.7MFY23 $-58.4MFY24 $-64.1MFY25 $-59.4M

EPS (Diluted)

+37.7% YoY

$-1.27FY 2025

FY22 $-1.91FY23 $-1.88FY24 $-2.04FY25 $-1.27

Total Assets

+340.1% YoY

$232.0MFY 2025

FY22 $122.4MFY23 $102.6MFY24 $52.7MFY25 $232.0M

Op. Cash Flow

+17.6% YoY

$-45.3MFY 2025

FY22 $-44.1MFY23 $-49.0MFY24 $-55.0MFY25 $-45.3M

Free Cash Flow

+17.4% YoY

$-45.5MFY 2025

FY22 $-44.8MFY23 $-49.3MFY24 $-55.1MFY25 $-45.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	—	—	$0.00 -100.0%	$317.0K -84.8%	$2.1M -10.0%	$2.3M
Net Income	$-56.0M +8.2%	$-61.0M -14.1%	$-53.5M -5.9%	$-50.5M -50.6%	$-33.5M -96.8%	$-17.0M
Operating Income	$-59.4M +7.3%	$-64.1M -9.7%	$-58.4M -12.9%	$-51.7M -52.7%	$-33.9M -98.4%	$-17.1M
EPS (Diluted)	$-1.27 +37.7%	$-2.04 -8.5%	$-1.88 +1.6%	$-1.91 +22.4%	$-2.46 +28.5%	$-3.44
Total Assets	$232.0M +340.1%	$52.7M -48.6%	$102.6M -16.2%	$122.4M -26.6%	$166.7M +333.9%	$38.4M
Operating Cash Flow	$-45.3M +17.6%	$-55.0M -12.3%	$-49.0M -11.0%	$-44.1M -42.9%	$-30.9M -111.0%	$-14.6M
Free Cash Flow	$-45.5M +17.4%	$-55.1M -11.7%	$-49.3M -10.0%	$-44.8M -45.1%	$-30.9M -110.7%	$-14.7M

Get alerted when IMRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Immuneering Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IMRX

FMR LLC
$48.4M9,704,610 sh
BlackRock, Inc.
$21.8M4,374,020 sh
Sanofi
$13.5M2,708,559 sh
VANGUARD CAPITAL MANAGEMENT LLC
$11.4M2,286,434 sh
PRICE T ROWE ASSOCIATES INC /MD/
$9.7M1,936,076 sh
GEODE CAPITAL MANAGEMENT, LLC
$6.8M1,370,750 sh
STATE STREET CORP
$5.0M1,001,995 sh
DCF Advisers, LLC
$3.9M790,000 sh
MARSHALL WACE, LLP
$3.7M731,897 sh
Connor, Clark & Lunn Investment Management Ltd.
$3.0M601,255 sh

Fund	Value	Shares
FMR LLC	$48.4M	9,704,610
BlackRock, Inc.	$21.8M	4,374,020
Sanofi	$13.5M	2,708,559
VANGUARD CAPITAL MANAGEMENT LLC	$11.4M	2,286,434
PRICE T ROWE ASSOCIATES INC /MD/	$9.7M	1,936,076
GEODE CAPITAL MANAGEMENT, LLC	$6.8M	1,370,750
STATE STREET CORP	$5.0M	1,001,995
DCF Advisers, LLC	$3.9M	790,000
MARSHALL WACE, LLP	$3.7M	731,897
Connor, Clark & Lunn Investment Management Ltd.	$3.0M	601,255

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IMRX on your watchlist

Track score changes the day Immuneering Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IMRX a good stock to buy?

13F Pro's AI-powered analysis of Immuneering Corp (IMRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IMRX are available on the IMRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IMRX is classified as a small company.

Which hedge funds own IMRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IMRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Immuneering Corp's investment landscape.